VyBio
Latest round
- Series B
Last raised
- Nov 2025
Total raised
- Undisclosed
Investors
- 2
About VyBio
, trading under VyBio or VyBio Therapeutics, operates as a pharmaceutical research and development company focusing on innovative drug discovery. Since inception, the company has centered its research pipeline on first-in-class and best-in-class therapeutics addressing oncology and chronic disease indications. Its founding and core scientific team includes drug discovery and clinical development specialists educated at institutions such as Tsinghua University, the University of California Los Angeles, the State University of New York, Sichuan University West China Medical Center and the University of Hong Kong. The company’s pipeline consists of novel therapeutic candidates targeting oncology and chronic disease treatment needs, several of which have entered Phase I and Phase II clinical trials. Its research activities include early-stage discovery, preclinical evaluation, and clinical development of drug candidates with global intellectual property protection. The company generates revenue primarily through pharmaceutical development activities, which include partnerships, licensing agreements, and collaboration with industry partners. The company plans to expand its pipeline for oncology and chronic diseases, accelerate ongoing clinical programs and enhance its capacity for global-standard clinical development.
Who invested in VyBio
2 investors across 2 rounds
See all investors in VyBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VyBio
Who invested in VyBio?
VyBio has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VyBio raised?
VyBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did VyBio last raise money?
VyBio's most recent round on record is a Series B, in Nov 2025.
What does VyBio do?
, trading under VyBio or VyBio Therapeutics, operates as a pharmaceutical research and development company focusing on innovative drug discovery.
Where is VyBio headquartered?
VyBio is headquartered in Hangzhou, China.
Which VCs invest in companies like VyBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at VyBio's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like VyBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.